Finanzen von Hemab Therapeutics Holdings Inc (COAG)COAGHemab Therapeutics Holdings Inc

In the context of the broader market, COAG competes directly with industry leaders such as NUVB and NVAX. With a market capitalization of $1.94B, it holds a leading position in the sector. When comparing efficiency, COAG's gross margin of N/A stands against NUVB's 70.11% and NVAX's 78.93%. Such benchmarking helps identify whether Hemab Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

Hemab has a current ratio of 35.85, indicating strong liquidity, but it has reported negative net income for the last four quarters, with Q2 2026 showing a loss of $24.15 million.